BJDX
Bluejay Diagnostics, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- B Mar 14 4 insiders buy $100.0K at $2.00
- E Jun 6 Offering: Bluejay Diagnostics Announces Closing of Up to $23.7 Milli…
- R Jun 29 The SEC declared effective the S-3 shelf registration (File No. 333-…
- B Jul 9 1 insider buy $96.7K at $1.51
- S Jul 10 1 insider sell $48.9K at $1.40
- X Aug 14 Short interest jumps 205.1% to 51.8K
- X Aug 31 Short interest jumps 411.7% to 265.1K
- X Sep 15 Short interest falls 50.4% to 131.5K
Signal stack
Where each data set points today.
- InsidersBULLISH
5 insiders bought $196.7K at an average $1.72. 1 insider sold $48.9K. Price is 68% below their cost.
- TrendDOWNTREND
35% below its 50-day average. New closing low $0.5600 on Oct 26.
Who's buying
13F| Top holder | Shares | Value |
|---|---|---|
| BANK OF AMERICA CORP /DE/ | 10,337 | $12.4K |
| VANGUARD FIDUCIARY TRUST CO | 10,225 | $12.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Aug 2023| Date | Firm | Rating |
|---|---|---|
| Aug 3, 2023 | Dawson James DOWNGRADE | Neutral |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 17, 2026 | CHASE DONALD R Director | AWARD | 100,000 sh |
| Aug 17, 2026 | ZEIDMAN FRED S Director | AWARD | 100,000 sh |
| Aug 17, 2026 | Dey Indranil President and CEO | AWARD | 28,000 sh |
| Aug 17, 2026 | Wurth Douglas Clark Director | AWARD | 100,000 sh |
| Aug 17, 2026 | Dey Svetlana Director | AWARD | 100,000 sh |
| Jul 10, 2026 | HRT FINANCIAL LP 10%+ Owner | SELL | $48.9K |
| Jul 9, 2026 | HRT FINANCIAL LP 10%+ Owner | BUY | $96.7K |
| Mar 14, 2026 | Dey Indranil President and CEO | BUY | $25.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
15 filings · 3 press releases · 3 bullish · 3 bearish · 9 neutral- NEUTRAL 8-KOct 13, 2026
Bluejay Diagnostics announced it has completed the establishment of a manufacturing site for…
This is a routine operational milestone with no financial data or regulatory clearance. Monitor for FDA 510(k) submission updates and SYMON-II pivotal study results for the next catalyst.
- NEUTRAL 8-KOct 6, 2026
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II pivotal study…
Watch for completion of SYMON-II IL-6 performance analyses and any subsequent 510(k) submission — the binary regulatory catalyst remains the key value driver for this pre-revenue stock.
- NEUTRAL 8-KAug 13, 2026
Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of SYMON-II pivotal…
Monitor for FDA 510(k) submission and any clinical data readouts from SYMON-II as the next catalysts. The cash runway into Q2 2027 provides a buffer but the stock remains binary on regulatory…
- NEUTRAL PRESS-RELEASEAug 13, 2026
Bluejay Diagnostics reported Q2 2026 results, highlighting completion of SYMON-II pivotal study…
The completion of SYMON-II enrollment and cash runway through Q2 2027 reduces near-term dilution risk, but the stock remains binary on FDA 510(k) clearance. Monitor for 510(k) submission timing and…
All BJDX filing & press-release reports (18)
- 8-K reportOct 13, 2026
- 8-K reportOct 6, 2026
- 8-K reportAug 13, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportJul 22, 2026
- 3 reportJul 13, 2026
- 3 reportJul 10, 2026
- EFFECT reportJun 29, 2026
- S-3 reportJun 17, 2026
- 8-K reportJun 9, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 5, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE, 8-K reportJun 2, 2026
- CLUSTER reportMay 18, 2026
- PRESS-RELEASE reportMay 7, 2026
- 8-K reportMay 7, 2026
- 8-K reportApr 7, 2026